Adverse events frequency associated with daptomycin treatment during OPAT – Full Text

"The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during daptomycin therapy is not well defined" Sunagawa et al (2026).

"The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during daptomycin therapy is not well defined" Sunagawa et al (2026).

ReTweet

Adverse events frequency associated with daptomycin treatment during OPAT

Abstract:

The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during daptomycin therapy is not well defined. We identified just 6.6 OPAT-AEs per 1000 sets of weekly laboratory tests in this population, suggesting that less intensive laboratory monitoring may be reasonable in patients receiving daptomycin for OPAT.

Reference:

Sunagawa SW, Hankins R, Kuck J, Frimpong S, Cortes-Penfield N, Lyden E, LeMaster M, Nguyen K, Alexander BT, Miller MM. Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Daptomycin. Open Forum Infect Dis. 2026 Jun 8;13(6):ofag254. doi: 10.1093/ofid/ofag254. PMID: 42266790; PMCID: PMC13243913.